Nuclear FGF2, androgen receptor and Wnt pathway activation define a targetable subset of antiprogestin-resistant luminal breast cancer. - Figueroa V; Coianis MI; Sahores A; Pataccini G; Abba MC; Elía A; May M; Vanzulli SI; Martínez Vázquez P; Burruchaga J; Torres F; Sartorius CA; et al. (British journal of cancer, 2026)